KDR and neoplasm: As a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, apatinib could strongly inhibit new angiogenesis in tumor tissue by highly selective compete the ATP binding site to block downstream signal transduction [3].